(Q33735451)

29 July 2017

1 reference

title

Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy (English)

1 reference

29 July 2017

Buske C

1

1 reference

29 July 2017

Feuring-Buske M

series ordinal

2

1 reference

29 July 2017

Unterhalt M

series ordinal

3

1 reference

29 July 2017

Hiddemann W

series ordinal

4

1 reference

29 July 2017

1 April 1999

1 reference

European Journal of Cancer

29 July 2017

1 reference

29 July 2017

35

1 reference

29 July 2017

4

1 reference

29 July 2017

549-557

1 reference

Recent cancer trends in the United States

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-frühe Stadien

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

What's the deal with follicular lymphomas?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Non-Hodgkin's lymphomas--current status of therapy and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Advances in monoclonal antibody therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Redesigning nature's poisons to create anti-tumor reagents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Pharmacokinetic modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Bacterial expression of immunoglobulin fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

90Yttrium antiferritin--a new therapeutic radiolabeled antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Phage libraries--a new route to clinically useful antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

Intensely cytotoxic anthracycline prodrugs: glucuronides

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900420-1

7 January 2021

10.1016/S0959-8049(98)00420-1

Identifiers

DOI

1 reference

29 July 2017

1 reference